Physician profile
Brian Dix
NPI 1700029519
$1,257.32
in general payments reported to CMS, 2019-2025
25 companies · $83.93 in 2025
The $83.93 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.47 · 2020: $106 · 2021: $184 · 2022: $325 · 2023: $317 · 2024: $147 · 2025: $83.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $266.11 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Pfizer INC. | $150.97 | 2022-2024 | |
| Organon LLC | $81.73 | 2022-2023 | Nexplanon |
| Astellas Pharma US INC | $76.26 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $62.82 | 2022-2025 | |
| Exeltis, USA INC. | $62.29 | 2022-2023 | Slynd |
| Millicent US INC | $53.67 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Therapeuticsmd, INC. | $52.55 | 2019-2022 | |
| Hologic Sales and Service, LLC | $52.52 | 2019-2023 | Myosure Tissue Removal Device |
| Amgen INC. | $47.43 | 2019-2023 | Evenity, Prolia |
| Shield Therapeutics INC | $44.40 | 2022-2024 | |
| Aspira Women'S Health INC | $38.41 | 2021 | |
| Ethicon US, LLC | $30.57 | 2021 | |
| Mylan Pharmaceuticals INC. | $30.16 | 2021-2022 | |
| Axsome Therapeutics, INC. | $27.43 | 2024 | Auvelity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $24.76 | 2024 | Perclot |
| Medtronic, INC. | $23.83 | 2023 | Interstim |
| Sage Therapeutics, LLC | $22.06 | 2023 | |
| Sumitomo Pharma America, INC. | $19.47 | 2025 | Myfembree |
| Medtronic USA, INC. | $18.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.36 | 2023 | |
| Myriad Women'S Health, INC. | $15.03 | 2023 | Myrisk |
| Novo Nordisk INC | $13.91 | 2024 | Wegovy |
| Myovant Sciences INC. | $12.10 | 2022 | |
| Amag Pharmaceuticals, INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Dix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.